Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Regulatory News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

8 May 2017 17:33

RNS Number : 5192E
Verona Pharma PLC
08 May 2017
 

 

 

 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: 

Verona Pharma plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

ü

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

 

3. Full name of person(s) subject to thenotification obligation: 

Growth Equity Opportunities IV, LLC

4. Full name of shareholder(s) (if different from 3.):

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

May 2, 2017

6. Date on which issuer notified:

May 5, 2017

7. Threshold(s) that is/are crossed orreached: 

8% to 9% change at direct interest level

     
 

 

8. Notified details:

A: Voting rights attached to shares 

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights 

Direct

Direct 

Indirect 

Direct

Indirect

Ordinary Shares

 

GB00B06GSH43

4,424,065

4,424,065

4,424,065

4,424,065

 

4.47%

 

 

US9250501064

 

 

5,333,328

5,333,328

 

5.39%

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate 

Exercise/Conversion Period 

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

 

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instrument

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date 

Exercise/Conversion period 

Number of voting rights instrument refers to

 

% of voting rights 

 

 

 

 

 

 

 

Nominal

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

9,757,393

9.86%

                 
 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: 

 

Growth Equity Opportunities IV, LLC is a limited liability company formed in the State of Delaware, United States

New Enterprise Associates 15, L.P., a limited partnership formed in the State of Delaware, is its sole member

NEA Partners 15, L.P., a limited partnership formed in the State of Delaware, is its general partner

NEA 15 GP, LLC, a limited liability company formed in the State of Delaware, is its general partner

 

 

Proxy Voting:

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will ceaseto hold:

 

12. Date on which proxy holder will cease to holdvoting rights:

 

 

13. Additional information:

Figures are based on a total number of 99,014,164 Ordinary Shares outstanding, as per the Company's Announcement of May 2, 2017.

14. Contact name:

Louis Citron, New Enterprise Associates

15. Contact telephone number:

+1 (410) 842-4000

   

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUGUBPAUPMGQR
Date   Source Headline
13th Sep 20167:00 amPRNHalf-year Report
12th Sep 20167:00 amPRNAppointment of Vikas Sinha as Non-Executive Director
30th Aug 20167:00 amPRNData on RPL554 to be presented at ERS Congress
10th Aug 20169:59 amPRNNotice of Results
9th Aug 20162:16 pmRNSDirector Dealing
5th Aug 20169:27 amRNSHolding(s) in Company
4th Aug 20163:26 pmPRNGrant of Share Options
4th Aug 20168:45 amRNSHolding(s) in Company
3rd Aug 20169:03 amRNSHolding(s) in Company
3rd Aug 20168:43 amRNSHolding(s) in Company
3rd Aug 20168:37 amRNSHolding(s) in Company
2nd Aug 20164:26 pmRNSHolding(s) in Company - Replacement
2nd Aug 201611:26 amRNSHolding(s) in Company
1st Aug 20163:57 pmRNSHolding(s) in Company
1st Aug 201611:40 amRNSHolding(s) in Company
1st Aug 201611:20 amRNSHolding(s) in Company
29th Jul 20168:06 amPRNAdmission of Placing Shares
22nd Jul 201611:32 amPRNResult of GM
1st Jul 20168:00 amPRNNotice of GM
27th Jun 20161:42 pmPRNResult of AGM
20th Jun 20167:00 amPRNProposed Placing and Notice of General Meeting
17th Jun 20164:54 pmPRNProposed Placing and Notice of General Meeting
3rd Jun 20165:26 pmPRN2015 Annual Report and Accounts, Notice of AGM
3rd Jun 20167:00 amPRNFinal Results
27th May 20162:48 pmPRNNotice of Results
10th May 20167:00 amPRNAdd-on Phase II RPL554 study
4th May 20167:00 amPRNVerona to present RPL554 at the ATS Conference
19th Apr 20163:16 pmPRNChange of Registered Office
15th Apr 20164:08 pmRNSHolding(s) in Company
21st Mar 20167:00 amPRNVerona Pharma: 2015 in review
15th Mar 20167:00 amPRNPositive results from RPL554 dose-finding study
10th Feb 20162:47 pmPRNGrant of Share Options
21st Jan 201612:24 pmRNSDirector Dealing
11th Jan 20167:00 amPRNDirectorate Change
3rd Dec 20154:02 pmPRNDirector Dealing
1st Dec 20155:11 pmRNSHolding(s) in Company
11th Nov 20157:00 amPRNRPL554 paper published in American Journal of Physiology
5th Nov 20157:00 amPRNPatient enrolment completed in RPL554 PhIIa studies
14th Oct 20157:00 amPRNStart of RPL554 Phase IIa combination study
8th Oct 201511:30 amPRNRPL554 data presented at North American CF Conference
29th Sep 20157:00 amPRNPositive headline data from RPL554 study
8th Sep 20157:00 amPRNBoard Changes
8th Sep 20157:00 amPRNHalf-yearly Report
27th Aug 20157:00 amPRNNotice of Results
7th Jul 20154:45 pmPRNDirector Dealing
17th Jun 20155:02 pmPRNDirector Dealings
12th Jun 20157:00 amPRNSecondary listing in Germany
11th Jun 20151:00 pmPRNResult of AGM
11th Jun 20157:00 amPRNRPL554 Phase 2a trial started
8th Jun 20157:00 amPRNRPL554 MAD study complete

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.